Ketamine, SGB and Combination Treatment for TBI

This randomised, double-blind, placebo-controlled trial (n=175) will investigate the efficacy of stellate ganglion block (SGB) and ketamine infusion, both separately and in combination, in treating post-traumatic stress disorder (PTSD) and traumatic brain injury (TBI)-associated headaches.

The study, sponsored by Northwestern University, aims to determine whether these interventions can provide relief for military personnel and veterans who have sustained injuries in conflicts.

Participants will be randomly assigned to one of four groups, receiving either SGB with bupivacaine, ketamine infusion, a combination of both, or placebo treatments. The primary outcomes will be assessed using the Headache Impact Test (HIT-6) and PTSD Checklist (PCL-5) at four weeks, with further follow-ups at eight and twelve weeks for responders. Additional exploratory measures, including neuroimaging and biomarker analysis, will be conducted to identify factors associated with treatment success. The study is expected to run from February 2025 to April 2028, with sites in the United States and Ukraine.

Topic Traumatic Brain Injury PTSD Neuroscience
Compound Ketamine Placebo
Country United States of America
Visit trial

Trial Details



Trial Number

Sponsors & Collaborators

Northwestern University
This company doesn't have a full profile yet, it is linked to a clinical trial.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.